In this work we studied the in vitro toxicity of + 8-[(4-Amino-1-Methylbutyl)Amino]-6-Methoxy-4-Methyl-5-[3,4dichlorophenoxy]quinoline (DN3-27-1) against stationary phase promastigotes Leishmania (L.) mexicana. Our results indicate that this drug induces an important reduction in parasite growth and killing compared to the reference drug N-methyl meglumine (Glucantime TM ). DN3-27-1 was not toxic to Hela cells cultured in vitro. This is the first report describing the promising potential of DN3-27-1 in treatment of L. (L.) mexicana infections.
The leishmaniases comprise a group of infectious diseases transmitted by the bite of infected sandflies. It is caused by Leishmania sp. an obligate intracellular flagellated protozoa [1] . According to a World Health Organization (WHO) report, the leishmaniases are widespread in 88 countries worldwide. Overall prevalence is about 12 million and the population at risk is around 350 million [2] . Worldwide, two million new cases occur each year, and in many endemic areas disease incidence is set to increase [3] .
The leishmaniases present a spectrum of clinical manifestations. Chiclero's ulcer is one of the existing forms of cutaneous leishmaniasis (CL) and is due to infection mainly by Leishmania (L.) mexicana (L. mexicana) that is highly endemic in some parts of Mexico and Central America [1, 4] . The disease often affects the ear dermis, causing necrosis and tissue destruction at the site of the infection [5] .
The most widely used drug to treat leishmaniasis in this region is meglumine antimoniate which is licensed under the commercial name of Glucantime™. Patients have restricted access to this drug. Furthermore, there are costs and toxicity issues associated with the use of this drug. Therefore, development of a more effective drug with low toxicity is currently an urgent need. Parasite resistance is also developing to first-line antimonial drugs in some endemic areas, particularly India and South America. In the Yucatan peninsula of Mexico, patients' access to this drug is not facile in addition it is toxic and expensive [1, [4] [5] [6] [7] 2, [8] [9] [10] [11] [12] Patients in Southern Mexico often rely on radical procedures such as battery liquid spread on the skin lesion and even cutting off the entire lesion with a heated blade. Therefore, WHO recognizes an urgent need for the discovery and development of new anti-leishmanial drugs that are non-toxic, effective and readily accessible [12] .
Plants and microbial organisms have long been used as natural sources for the discovery of new drugs [7, 13] . Artemisinin and quinine are examples of plant derived products with antiparasitic activity [14, 15] . 8-aminoquinolines are an important class of alkaloids with promising anti-plasmodial activity and have been used in the treatment of other infectious diseases [16] .
Numerous efforts towards the development of 8-aminoquinolines analogs have been accomplished by different research groups for treatment of protozoal infections [16] [17] . This initiative has led to the discovery of lepidines with antileishmanial activity in a hamster infection model with L. donovani [18] . Berberine and 8cyanodihydroberberine have showed significant activity against L. (V.) panamensis in golden hamsters [19] and tafenoquine has proved to be effective for prophylaxis against malaria infections, whereas sitamaquine is useful for treatment of visceral leishmaniasis [20] .
In this work the role of racemate + 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4dichlorophenoxy]quinoline (DN3-27-1) in the in vitro growth and eventual killing of logarithmic phase promastigotes of L. mexicana was studied.
Leishmanicidal activity:
The racemate + 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4dichlorophenoxy]quinoline ( Figure 1 ) displays strong in vitro toxicity against L. mexicana. Our results show that parasite growth is dramatically compromised at very low doses of the 8-quinolone tested in this work ( Figure 2 ). One million log phase promastigotes were seeded in one mL of complete RPMI-1640 media and parasite numbers, mobility and morphology were measured from 24 to 120 hr. Parasite replication was clearly reduced at 48 hr and onwards after treatment with this drug as compared to the control group. Treatment with the quinoline showed significant increase in leishmanicidal activity in comparison to the antimonial reference drug ( Figure 2 ).
Results from the in vitro evaluation of mobility demonstrated that promastigotes were inhibited within the first 24 hr and onwards after parasite treatment with the 8-aminoquinolone tested (Table 1) . Parasite morphology as measured in parasites length and perimeter showed significant reduction after treatment with various doses of this product ranging from Significant differences in parasites body-morphology, measured by length and perimeter, between tests and control are indicated with an asterisk and were recorded using the Dunnett statistical procedure. Data are expressed as mean ± SEM, n= 15. *p< 0.05;**p< 0.001. N.D = Not done 1 to 100 µg/mL (Table 2) . Interestingly, the LD 50 of the 8-aminoquinolone was significantly less than the corresponding LD 50 for the reference antimonial drug after 48 hrs of treatment. For DN3-27-1 the recorded value for LD 50 was 0.4486 µg/mL and the value for the antimonial drug was 250.5 µg/mL.
Cytotoxic activity of DN3-27-1 and the reference drug to in vitro cultured Hela cells was negligibly over a period of 120 hr. The rate of growth, refringence and integrity of the monolayer of Hela cells cultured with 10 and 100 µg/mL of DN3-27-1 or glucantime were not Leishmanicidal activity of a synthetic 8-aminoquiniline derivative Natural Product Communications Vol. 5 (3) 2010 389 different from those of control cultures. Cell viability using the trypan blue exclusion test showed similar results between control and experimental cultures (>90%) after 120 hr of culture.
There are just a few reports on the leishmanicidal action of some 8-aminoquinoline analogs against some species of Leishmania [16, 21] . However, to our knowledge, this is the first report demonstrating the in vitro killing activity of racemate + 8-[(4-amino-1-methylbutyl) amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy] quinoline against L. mexicana promastigotes.
The mechanism of action of primaquine has been related to the production of hydrogen peroxide and reactive oxygen intermediates in erythrocytes [16] . However, the mechanism of action of DN3-27-1 studied in this work and individual enantiomers on the parasite Leishmania remains to be elucidated. Previous work separated the racemate and provided two enantiomerically pure isomers [16] , one, the (-) enantiomer is even more effective treating experimental visceral leishmaniasis induced with L. donovani in HU3 mice. The (-) enantiomer also displays less toxicity than the (+) enantiomer in the Beagle dog [16] . Future research will be directed at the study of DN3-27-1 and its individual enantiomers for their in vivo ability to inhibit the progression of cutaneous leishmaniasis provoked by L. mexicana infections in animal models and this might lead to future clinical trials in humans living in endemic areas for this parasitic infection.
Experimental
Parasites: Leishmania (L.) mexicana (MHOM/MX/84/ ISETGS) was obtained by in vitro culture of amastigotes in RPMI-1640 supplemented with 10% fetal calf serum (FCS, Sigma, USA) and incubated at 28ºC.
Compound studied:
The compound + 8-[(4-amino-1methylbutyl)amino]-6-methoxy-4-methyl-5- [3,4dichlorophenoxy] quinoline. This chemical compound is coded as DN3-27-1 and was synthesized as previously described (21) .
Viability, mobility and morphology test of L. mexicana promastigotes:
DN3-27-1 and the reference drug Glucantime TM (N-methyl glucamine, Sanofi Aventis S.A.U.) were dissolved in a known volume of DMSO (Dimethylsulfoxide; Sigma, U.S.A.) and diluted (1%) with culture medium. One million infective log phase promastigotes were cultured together with 100, 10, 1, 0.1 and 0.01µg/mL of DN3-27-1 or 100 µg/mL of glucantime (used as reference drug). As control, parasites were suspended in complete culture media containing 1% DMSO. Parasites so treated were counted in triplicate, for five days, using a hemacytometer and a vertical microscope (40X objective). Morphology of parasites' body and mobility was assessed, in the same culture, by daily measurement of parasites' length and perimeter of 15 randomly selected parasites per group using a computer program linked to a Telaval II inverted microscope (Axiodoc-A, Carl-Zeiss, Germany), calibrated according to the manufacturer's instructions.
Cytotoxicity studies:
The cytotoxic activity was examined using Hela cells. This cell line was cultured in vitro in RPMI-1640 media supplemented with 10% FCS and incubated at 37ºC with 5% CO 2 . Tissue culture plates (24 well plates, Falcon U.S.A.) were seeded at 5 X 10 4 cells/well in culture media. DN3-27-1 or glucantime were added at a concentration of 100 and 10 μg/mL, and were observed every day for four weeks. The monolayer of Hela cells suspended only in culture media with 1% DMSO was used as control. Trypan exclusion test was also performed on both Hela cells treated with DN3-27-1 or control with no differences in viability between these groups.
LD 50 values: The LD 50 was determined by counting living promastigotes after an incubation period of 48 hours. Data were analyzed with a computer program LdP Line ® .
Statistics:
Statistical analysis was performed using the Dunnett test.
